Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals Inc. develops biotechnology drug candidates through a biology-centric discovery engine that combines disease biology and protein engineering. Company news has centered on clinical and regulatory updates for its pipeline, including NGM707, a dual ILT2/ILT4 antagonist antibody evaluated in advanced or metastatic solid tumors, and aldafermin development in primary sclerosing cholangitis and other rare-disease strategy discussions.
Recurring updates also include oncology conference presentations, clinical-data posters, operating and financial results, governance matters, capital-structure disclosures, shareholder voting matters and material agreements. Corporate-action news includes the completed cash tender offer by an affiliate of The Column Group for shares of NGM Bio not already held by affiliates and certain other stockholders.
NGM Biopharmaceuticals (NGM) announced the expansion of its oncology portfolio with NGM707, a novel dual antagonist antibody targeting ILT2 and ILT4, which may enhance anti-tumor immune responses. First-in-human testing is planned for mid-2021. NGM707 aims to combat myeloid cell immune suppression implicated in immune evasion by tumors. This new candidate complements NGM120, currently in clinical trials. NGM's R&D Day is scheduled for December 9, 2020, to showcase its pipeline, which addresses various diseases, including cancer.
NGM Biopharmaceuticals (NGM) announced positive results from its 24-week Phase 2 study of aldafermin in patients with non-alcoholic steatohepatitis (NASH). The study showed a statistically significant reduction in liver fat content and improvements in liver fibrosis, with a favorable safety profile. Notably, 30% of patients with advanced liver fibrosis (F3) exhibited significant fibrosis improvement. NGM plans to report topline data from its Phase 2b ALPINE 2/3 study in Q2 2021, aiming to further validate aldafermin's potential as a transformative treatment for NASH.
NGM Biopharmaceuticals, Inc. (NGM) announced that data from its 24-week Phase 2 study of aldafermin in non-alcoholic steatohepatitis (NASH) will be presented at The Digital International Liver Congress 2020 from August 27-29. The presentation includes positive topline results and new analyses. Additionally, several related poster presentations will showcase findings on biomarkers and improvements in non-invasive tests due to aldafermin therapy. This highlights NGM's ongoing commitment to developing transformative therapeutics for liver diseases.
NGM Biopharmaceuticals (NGM), a biotechnology company, has announced that CEO David J. Woodhouse, Ph.D., will present a business update at two upcoming investor conferences. The presentations will take place on August 10, 2020, at the BTIG Biotechnology Conference at 11:00 am ET, and on August 13, 2020, at the Canaccord Genuity 40th Annual Growth Conference at 9:00 am ET. A live webcast of these presentations will be available on NGM's website, with a replay accessible for 30 days post-event.
NGM Biopharmaceuticals, focused on transformative therapeutics, announced that CEO David J. Woodhouse will present an overview and business update at two investor conferences. The events are scheduled for June 3, 2020, at the Jefferies Virtual Healthcare Conference at 3:30 pm ET, and June 10, 2020, at the Goldman Sachs 41st Annual Global Healthcare Conference at 1:20 pm ET. A live webcast will be available on their website, with a replay accessible for 30 days post-event.
NGM Biopharmaceuticals will host its 2020 Annual Meeting of Stockholders as a virtual-only event on May 20, 2020, at 7:30 a.m. PDT due to COVID-19 safety concerns. Stockholders of record as of March 23, 2020, can participate via a live audio webcast, starting at 6:30 a.m. PDT. The company emphasizes the same rights for stockholders as in-person attendance. Instructions for participation, voting, and accessing the meeting are detailed, with a reminder to submit proxies in advance. The meeting will be archived for one year.